ABL1 and Parkinson disease: She continued nilotinib for 5 years and remained in profound molecular remission (MR4,5 on the BCR::ABL1 0.5% International Scale), until she developed parkinsonism, which was initially thought to be drug‐related, i.e., attributed to nilotinib.